Marketing authorisation holder: BioNTech
Date of marketing authorisation: 21 December 2020
On 8 January 2021, the Summary of Product Characteristics (SmPC) was updated in order to allow to extract 6 (instead of previously 5) doses per container.
Marketing authorisation holder: Moderna
Date of marketing authorisation: 06 January 2021
Marketing authorisation holder: AstraZeneca
Date of marketing authorisation: 29 January 2021
The Austrian National Vaccination Panel recommends the use of Astra Zeneca's vaccine in the 18-64 age group.
For the 65+ age group, immunologic and safety data are comparable to those for younger individuals.
Due to the small group size and the low number of cases of disease, it is not possible at this time to make a safe prognosis for this age group.
Information about authorised Covid-19 vaccines and those under evaluation can be found on the website of the European Medicines Agency (EMA).